News

Podcast: Newly approved drug may slow progression of Alzheimer’s

Washington University School of Medicine in St. Louis - Aug 4, 2023

Lilly drug slows Alzheimer’s by 35%, bolstering treatment approach

Reuters - May 8, 2023

Conquering Alzheimer’s: a look at the therapies of the future

Nature - Apr 4, 2023

Seeking Alzheimer’s clues from few who escape genetic fate

AP News - March 16, 2023

Lifetime Achievement Award

Clinical Trials on Alzheimer's Disease (CTAD) - March 14, 2023

Focused ultrasound technique leads to release of neurodegenerative disorders biomarkers

The Source, Washington University in St. Louis - Feb 3, 2023

Update on the DIAN-TU-001 Trial with E2814 and Lecanemab (Eisai Co., Ltd)

The statement below is in response to Eisai’s 06 January 2023 announcement regarding the FDA’s accelerated approval of lecanemab for...

FDA APPROVES LEQEMBI™ (LECANEMAB-IRMB) UNDER THE ACCELERATED APPROVAL PATHWAY FOR THE TREATMENT OF ALZHEIMER’S DISEASE

Eisai Co., Ltd. - Jan 06 2023

Update on the DIAN-TU-002 Primary Prevention Trial

20 December 2022 Update on the DIAN-TU-002 Primary Prevention Trial The statement below is an update to the 15 November...

WashU, Eisai form drug discovery collaboration

The Source, Washington University in St. Louis - Dec 14, 2022